An innovative study mapped preterm births, low birth weights and infant mortality to municipal water wells downstream from PFAS-contaminated sites. The results show the high cost of PFAS harm.
More parents are refusing vitamin K shots for their newborns, a study published Monday in the Journal of the American Medical Association found. It’s a trend that experts worry could have deadly consequences
The Nordic countries are no strangers to the long, dark winter. Despite little to no daylight — plus months of frigid temperatures — people who live in northern Europe and above the Arctic Circle have learned how to cope mentally and physically with the annual onset of the winter blues, which can begin as early as October and last into April for some. The winter solstice will occur Dec. 21, marking the shortest day and longest night of the year in the Northern Hemisphere.
The following is the transcript of the interview with former FDA commissioner Scott Gottlieb, who now serves on the boards of Pfizer and United Healthcare, that aired on "Face the Nation with Margaret Brennan" on Dec. 7, 2025.
The nascent LGBTQ+ rights movement and the Christian right each strongly shaped the early years of HIV/AIDS, a historian explains.
Spiritual leaders’ own pain often goes unnoticed as they tend to their community’s challenges.
The outbreak blamed on "gym exposure" is relatively small, but it has helped push cases tied to the Legionella bacteria to a 10-year high in Florida.
Synchronizing your daily activities to your circadian rhythm could help you improve your performance on a variety of cognitive tasks − and even influence diagnosis of cognitive disorders.
As it is now, the transplant system treats kidneys from all Black donors as if they are at higher risk for failing, even though only some are.
Dec 6 () - Regeneron said on Saturday its experimental cancer combination therapy was effective and showed disappearance of the disease in previously untreated patients with a type of blood cancer in the first part of a late-stage trial. The trial, which enrolled 22 patients, studied safety and preliminary efficacy of the company's therapy, odronextamab, in combination with chemotherapy in patients with Diffuse Large B-Cell Lymphoma or DLBCL.